Health Disparities in Mesothelioma
Health Disparities in Mesothelioma
Overview
Health disparities in mesothelioma are systematic differences in diagnosis, treatment access, and survival outcomes driven by race, socioeconomic status, geography, gender, insurance coverage, and facility type.[1] The largest population-based studies reveal that Black mesothelioma patients receive cancer-directed surgery at significantly lower rates, are diagnosed at later stages, and face compounding barriers to specialized care — even when disease characteristics are comparable.[2][3] Geographic disparities concentrate disease burden in communities near shipyards, mines, and industrial corridors, while access to the 15–20 specialized mesothelioma centers in the United States is limited primarily to patients in major metropolitan areas.[4][5] Gender differences produce a striking survival advantage for women, but this advantage disappears in Black female patients — a finding that underscores the intersectional nature of mesothelioma inequities.[2][6] Environmental justice failures in communities like Libby, Montana and Ambler, Pennsylvania demonstrate how asbestos exposure disproportionately affects economically disadvantaged populations with the fewest resources to access specialized legal and medical care.[7][8] Understanding these disparities is essential for patients and families navigating treatment options and pursuing compensation within applicable filing deadlines.[9]
Health disparities in mesothelioma at a glance:
- Black patients are 80% more likely to die — even after adjusting for age, stage, income, education, and facility type, race remains the single strongest mortality predictor
- Surgery access gap persists at every disease stage — Black patients receive cancer-directed surgery 25% less often than White patients, and when surgery is received, outcomes are equivalent
- Income above 150% of poverty level means 18% longer survival — but this effect disappears after adjusting for race and facility type, meaning where you are treated matters more than what you earn
- Academic cancer centers cut five-year mortality by nearly 40% — yet only 15–20 institutions nationally maintain dedicated mesothelioma programs
- Women survive more than twice as long as men — 16% five-year survival versus 7%, driven by hormonal, histologic, and age-at-diagnosis differences
- The female survival advantage vanishes for Black women — HR 1.10 compared to HR 0.82 for White women, suggesting unmeasured systemic barriers override biological protection
- Patient navigation triples minority clinical trial enrollment — from 13% to 41% for Black patients, proving that structural barriers are modifiable
- Wisconsin, Pennsylvania, Minnesota, and Michigan bear the highest per capita burden — clustered around shipbuilding, manufacturing, and mining infrastructure
- Libby, Montana residents died at 40–80 times normal asbestos disease rates — the most extreme U.S. case of environmental exposure affecting an economically disadvantaged community
Key Facts
| Key Facts: Health Disparities in Mesothelioma |
|---|
|
How Do Racial Disparities Affect Mesothelioma Outcomes?
Racial disparities in mesothelioma manifest across incidence, diagnosis timing, treatment access, and survival — creating compounding disadvantages for minority patients.[14][2]
Incidence and Diagnosis
The SEER population-based analysis of 13,166 patients (2000–2019) found that mesothelioma is overwhelmingly a disease of White patients, who comprise 91.3% of cases.[10] Age-adjusted incidence rates differ substantially: White 1.1 per 100,000 versus Black 0.5 per 100,000 (p=0.01), reflecting differential historical occupational exposure patterns.[2] However, among Asian/Pacific Islanders, 59.7% of diagnoses occurred after 2010 versus 40.3% before 2010 (p<0.001), suggesting a rising or stable incidence in this group while overall U.S. incidence continues declining.[15]
Black patients are diagnosed at more advanced stages: 65% present with distant disease versus 59% of White patients (p=0.002).[2] Potential explanations include delays in seeking care, reduced access to diagnostic procedures, insurance coverage gaps, and possibly different symptom presentation patterns.[1][11]
Treatment Access
The treatment gap is the most consequential racial disparity in mesothelioma. The Taioli SEER analysis (n=13,734) found that Black patients received cancer-directed surgery at 18% versus 24% for White patients (p=0.001) — a disparity that persisted at every disease stage:[2]
| Disease Stage | White Surgery Rate | Black Surgery Rate |
|---|---|---|
| Localized | 31.5% | 29.3% |
| Regional | 37.5% | 33.0% |
| Distant | 21.4% | 15.1% |
| Unknown Stage | 10.2% | 7.0% |
The Mount Sinai NCDB study (n=2,550 surgical patients) found that Black patients were significantly less likely to receive extrapleural pneumonectomy (adjusted OR 0.36, 95% CI: 0.17–0.78).[16] Critically, among patients who did receive surgery, there was no significant survival difference by race (HR 0.99, 95% CI: 0.71–1.38), demonstrating that the disparity lies in access, not in surgical outcomes.[16][17]
Survival
After adjusting for age, sex, stage, surgery, and radiation, Black and White patients had comparable overall survival — but the interaction between race and prognostic factors revealed important differences.[2] In White patients, female gender (HR 0.82), younger age, and early stage were all independent predictors of longer survival. In Black patients, only younger age and receipt of surgery predicted improved survival — female gender and early stage provided no survival benefit.[2]
The Rodriguez et al. JAMA Network Open study (n=1,389 operable patients) found that Black race was the single strongest predictor of mortality: HR 1.96 (95% CI: 1.43–2.69), persisting after adjustment for every available clinical and socioeconomic variable.[3] Surgery improved overall survival by 30%, but many patients — disproportionately Black — were never referred for surgical evaluation.[3][5]
What Role Does Socioeconomic Status Play?
Socioeconomic factors interact with race to create layered disadvantages in mesothelioma outcomes.[9][11]
Income and Insurance
Patients with incomes above 150% of the federal poverty level experienced approximately 18% better survival in unadjusted analysis.[3] However, this income effect lost statistical significance after multivariate adjustment — race and facility type captured most of the socioeconomic effect, suggesting that income operates primarily through its influence on where patients receive care.[3]
Insurance type is a powerful independent predictor of mesothelioma outcomes. Privately insured patients have significantly better survival than those on Medicaid or uninsured, with uninsured patients having approximately half the odds of receiving any treatment (OR 1.93 favoring private insurance).[11] Given that Black patients are more likely to be uninsured or on Medicaid, insurance status functions as a mediating variable that amplifies racial disparities.[11][18]
Facility Type
Where a patient receives treatment is among the strongest modifiable predictors of survival. A National Cancer Database analysis of peritoneal mesothelioma found 5-year survival of 29.7% at academic/NCI centers versus 18.3% at community facilities.[12] Treatment at a community facility was independently associated with higher mortality (HR 1.19), and academic centers offered debulking surgery at more than double the rate of community hospitals (42.9% versus 20.2%).[12]
| The Travel Distance Paradox: Patients who travel farther to high-volume surgical centers paradoxically survive longer (HR 0.92), reflecting the survival benefit of specialized care rather than a proximity effect.[3] This finding underscores the importance of seeking mesothelioma-specific expertise even when it requires significant travel.[19] |
Rural Versus Urban Access
Rural patients face significant barriers to mesothelioma specialist access. NCI-designated cancer centers with dedicated mesothelioma programs are concentrated in major metropolitan areas — New York, Houston, Boston, Los Angeles, Philadelphia, and Chicago — creating vast access deserts across rural America.[5][20] A 2025 study found that nonmetropolitan patients were more likely to be non-Hispanic Black and had lower rates of both chemotherapy (p=0.031) and surgery (p<0.001) compared to metropolitan patients.[2] Only 2% of patients in the Rodriguez JAMA cohort were from rural areas, making powered analysis of rural-specific outcomes impossible — itself an indicator of the access problem.[3]
Where Are Geographic Disparities Most Severe?
Mesothelioma burden concentrates in communities with shipbuilding, manufacturing, and mining histories, creating geographic clusters that persist decades after peak exposure periods.[4][14]
State-Level Rankings
| Rank | State | Per Capita Rate | Primary Exposure Sources |
|---|---|---|---|
| 1 | Wisconsin | 1.24 per 100,000 | Manufacturing, paper mills |
| 2 | Pennsylvania | 1.22 per 100,000 | Shipyards, steel mills, asbestos manufacturing |
| 3 | Minnesota | 1.20 per 100,000 | Iron Range mining, manufacturing |
| 4 | Michigan | 1.18 per 100,000 | Auto manufacturing |
| — | Maine (death rate) | 22.06 per million | Bath Iron Works, Portsmouth Naval Shipyard |
California reported 298 mesothelioma cases in 2022 — more than any other state by absolute count — driven by its population size, naval installations, and industrial diversity.[4]
Hotspot Communities
Several communities bear disproportionate mesothelioma burden due to concentrated industrial or environmental exposure:[4][21]
- Shipyard communities: Bath, Maine; Norfolk, Virginia; Bremerton, Washington; Pascagoula, Mississippi — where naval shipbuilding created decades of intensive asbestos exposure for workers and surrounding neighborhoods
- Mining areas: Libby, Montana (vermiculite/amphibole asbestos); Iron Range, Minnesota — where mineral extraction contaminated both workplace and community environments
- Industrial corridors: Pennsylvania steel belt; Ambler, Pennsylvania (asbestos manufacturing legacy from the 1880s through mid-20th century) — where factory operations released asbestos into residential areas
How Do Gender Differences Affect Outcomes?
Gender disparities in mesothelioma extend beyond the well-known difference in incidence to include survival advantages, exposure pathway differences, and biological factors that are modified by race.[6][18]
The Female Survival Advantage
Women with mesothelioma consistently survive longer than men, with 5-year survival rates of approximately 16% versus 7% and median survival of 22 months versus 14 months.[6] Female gender is an independent predictor of longer survival in White patients (HR 0.82, 95% CI: 0.77–0.88), but this advantage was not observed in Black female patients (HR 1.10, 95% CI: 0.84–1.44).[2]
Several biological and demographic factors contribute to the female advantage:[6][22]
- Histologic distribution: Women have higher rates of epithelioid histology (35.7% versus 30.9%, p<0.0001), which carries better prognosis
- Younger age at diagnosis: 22.1% of women are diagnosed under 65 versus 19.7% of men
- Hormonal protection: Estrogen receptor-β (ER-β) expression in tumors is associated with significantly better survival (HR 5.4 for negative versus positive expression, p=0.002); premenopausal women with peritoneal mesothelioma outlive postmenopausal women
- Peritoneal proportion: Women represent 20.5% of peritoneal cases versus 8.1% of pleural cases, and peritoneal mesothelioma responds better to cytoreductive surgery[4][23]
Exposure Pathway Differences
Non-occupational exposure pathways — particularly secondary (take-home) exposure where asbestos fibers are brought home on workers' clothing — disproportionately affect women.[24] The Italian National Mesothelioma Registry (n=21,463) found that non-occupational exposure was the predominant pathway in 45.3% of female cases, compared to occupational exposure in 78.2% of male cases.[24]
Research from the University of Pennsylvania Superfund Research Program found that women in the Ambler, Pennsylvania community had a greater risk of mesothelioma than men — a reversal of the typical gender pattern — driven by environmental rather than occupational exposure from nearby asbestos manufacturing operations.[8][25]
Male mesothelioma incidence is declining at approximately 1.8% per year, reflecting reduced occupational exposure. Female incidence remains largely unchanged, and the CDC MMWR reported that mesothelioma deaths among women actually increased from 1990 to 2020.[26][15] This diverging trend suggests that non-occupational exposure pathways have not been adequately addressed.
Why Is Clinical Trial Access Unequal?
Clinical trial participation — the pathway to newer therapies including immunotherapy combinations — is marked by significant racial and socioeconomic disparities that compound the treatment gaps observed in standard care.[13][19]
Representation Gaps
Approximately 6% of U.S. cancer patients participate in clinical trials.[20] A 2023 analysis of 93 U.S.-based oncology trials found that non-Hispanic White patients comprised 82.3% of enrollees, while Black patients represented only 10% and Hispanic patients as low as 1% — despite representing 13% of the national cancer population.[13] For mesothelioma specifically, trial enrollment data disaggregated by demographics is extremely limited, but given the disease's rarity and the concentration of trials at major academic centers, access barriers are amplified for minority patients.[27]
Barriers and Solutions
Multiple structural barriers limit trial diversity:[13][27]
- Awareness: Lack of clinical trial awareness, particularly in minority communities, means eligible patients are never informed of available trials
- Trust: Historical mistrust of healthcare systems rooted in past injustices affects willingness to participate
- Restrictive eligibility: Black ineligibility rates are higher than White rates even for diseases with higher Black incidence
- Geographic concentration: Trial sites cluster in major urban centers; states with highest minority populations may have fewer sites
- Financial barriers: Travel costs, lost wages, and insurance gaps make sustained trial participation economically prohibitive
- Language: Lack of concordance between clinical trial teams and patients with limited English proficiency
Patient navigation programs have demonstrated the most compelling evidence for reducing these barriers. At one center, pre-navigation trial enrollment was 19% for rural patients, 13% for Black patients, and 5% for Hispanic patients; post-navigation enrollment rose to 40%, 41%, and 33% respectively.[13] The FDA Diversity Action Plan requirement (effective 2024) now mandates sponsors to submit plans for ensuring meaningful representation in clinical trials.[27][28]
What Are the Environmental Justice Implications?
Environmental justice failures in asbestos-affected communities demonstrate how industrial contamination disproportionately impacts economically disadvantaged populations with the least access to specialized medical and legal resources.[14][8]
Superfund Sites and Community Demographics
A 2024 PNAS Nexus study analyzing 1,688 Superfund sites found that race — not class — is the major indicator of environmental inequality in remediation, with Asian population proportion negatively associated with cleanup status.[29] Asbestos-related Superfund sites are among the most complex and long-lasting remediation challenges in the EPA system, with some communities facing decades of ongoing monitoring after waste piles are capped rather than removed.[8]
Libby, Montana
Libby represents the most extreme U.S. case of community-wide asbestos exposure. Among 1,672 white male vermiculite workers hired between 1935 and 1981, standardized mortality ratios were dramatically elevated: asbestosis 165.8 (95% CI: 103.9–251.1), cancer of the pleura 23.3 (95% CI: 6.3–59.5), and lung cancer 1.7 (95% CI: 1.4–2.1).[7]
The Libby community's socioeconomic profile compounds its health burden: a rural, economically disadvantaged community with limited access to specialized medical care. The ATSDR found that 6.7% of community residents with no occupational or familial exposure had radiographic evidence of asbestos-related disease, demonstrating widespread environmental contamination affecting people who never worked with asbestos.[7][30]
Ambler, Pennsylvania
The Ambler community in Montgomery County, Pennsylvania is surrounded by the BoRit Asbestos Superfund Site, a legacy of asbestos manufacturing from the late 1880s through the mid-20th century.[8][31] The University of Pennsylvania Superfund Research Program received a $10 million NIEHS grant in 2014 — the first NIEHS Superfund grant driven by community-identified problems — to study asbestos exposure pathways and health consequences in the surrounding population.[8]
The Pennsylvania Department of Health identified increased mesothelioma rates in Ambler-area zip codes compared to adjacent communities, with women showing greater mesothelioma risk than men — a reversal that reflects environmental rather than occupational exposure dominance.[8][32] Researchers are mapping the entire 1930 population to track long-term health outcomes of former residents, a project that could provide unprecedented data on environmental asbestos exposure and mesothelioma risk across generations.[8]
Frequently Asked Questions
Are mesothelioma outcomes equal across racial groups?
No. The JAMA Network Open study of 1,389 operable patients found that Black race was the single strongest independent predictor of mortality (HR 1.96, 95% CI: 1.43–2.69), persisting after adjustment for age, stage, income, education, and facility type.[3] Black patients receive cancer-directed surgery at 18% versus 24% for White patients, and 73% of Black patients receive no treatment at all compared to 68% of White patients.[2] Critically, when Black patients do receive surgery, their survival is equivalent to White patients — demonstrating that the disparity is in access, not in treatment response.[16][1]
How does insurance status affect mesothelioma treatment?
Insurance type is a powerful predictor of whether a patient receives any treatment at all. Uninsured patients have approximately half the odds (OR 1.93 favoring private insurance) of receiving cancer-directed treatment.[11] Patients with private insurance have significantly better survival than those on Medicaid or uninsured. Since mesothelioma treatment often involves complex multimodal therapy at specialized centers, insurance barriers compound geographic and socioeconomic obstacles.[11][9]
Why do academic cancer centers produce better mesothelioma outcomes?
Academic and NCI-designated cancer centers achieve 29.7% five-year survival for peritoneal mesothelioma versus 18.3% at community facilities, largely because they offer debulking surgery at more than double the rate (42.9% versus 20.2%).[12] These centers maintain dedicated mesothelioma tumor boards, specialized thoracic and peritoneal surgeons, access to clinical trials, and multidisciplinary treatment teams — infrastructure that community hospitals cannot replicate for a disease affecting fewer than 3,000 Americans annually.[20][5]
Do women survive mesothelioma longer than men?
Yes, by a significant margin. Women achieve 5-year survival of approximately 16% versus 7% for men, with median survival of 22 months versus 14 months.[6] Contributing factors include higher rates of epithelioid histology (35.7% versus 30.9%), younger age at diagnosis, hormonal protection through estrogen receptor-β expression, and greater representation in peritoneal mesothelioma which responds better to cytoreductive surgery.[22][4] However, this survival advantage disappears in Black female patients, whose HR is 1.10 compared to 0.82 for White females.[2]
What states have the highest mesothelioma rates?
Wisconsin (1.24/100K), Pennsylvania (1.22/100K), Minnesota (1.20/100K), and Michigan (1.18/100K) have the highest per capita mesothelioma incidence, clustered around manufacturing, shipbuilding, and mining regions.[4] Maine has the highest death rate at 22.06 per million residents, driven by exposure at Bath Iron Works and Portsmouth Naval Shipyard.[4] California has the most cases by absolute count (298 in 2022) due to its population size, naval installations, and industrial diversity.[4][21]
Are minority patients underrepresented in mesothelioma clinical trials?
Severely. Across U.S. oncology trials, non-Hispanic White patients comprise 82.3% of enrollees while Hispanic patients represent as low as 1% despite accounting for 13% of cancer patients nationally.[13] Mesothelioma-specific trial data disaggregated by race is not published, but given the concentration of trials at major academic centers and the disease's rarity, minority patients face amplified access barriers. Patient navigation programs have demonstrated that enrollment disparities are modifiable — tripling Black enrollment from 13% to 41% and Hispanic enrollment from 5% to 33%.[13][27]
What is environmental justice and how does it relate to asbestos exposure?
Environmental justice addresses the disproportionate exposure of minority and economically disadvantaged communities to environmental hazards, including asbestos contamination. A 2024 PNAS Nexus study found that race — not class — is the major indicator of environmental inequality in Superfund site remediation.[29] Communities like Libby, Montana and Ambler, Pennsylvania demonstrate how asbestos exposure burdens are concentrated in populations with the fewest resources to access specialized medical care and legal compensation.[7][8][30]
How can patients overcome geographic barriers to specialized care?
The travel distance paradox in mesothelioma research shows that patients who travel farther to high-volume centers survive longer (HR 0.92), reflecting the benefit of specialized expertise.[3] Telemedicine expanded access during the COVID-19 pandemic, potentially enabling multidisciplinary tumor board participation via teleconference for community oncologists.[5] Patient navigation programs, which assign dedicated staff to coordinate specialist referrals, travel logistics, and insurance authorization, have demonstrated dramatic improvements in treatment access for underserved populations.[13] Patients should seek evaluation at an NCI-designated cancer center with a dedicated mesothelioma program regardless of geographic location.[1]
Quick Statistics
- U.S. mesothelioma diagnoses declined from 3,247 in 2003 to 2,669 in 2022, but burden remains concentrated in industrial communities[4]
- Total U.S. mesothelioma cases 2003–2022: 63,620 (47,973 male, 15,647 female)[4]
- Black mortality decline was two-fold that of Whites over the 2000–2019 period, reflecting greater reduction in occupational exposure[15]
- Asian/Pacific Islander mesothelioma diagnoses: 59.7% occurred after 2010 versus 40.3% before 2010 (p<0.001), suggesting stable or rising incidence[15]
- Male mesothelioma incidence declining at approximately 1.8% per year; female incidence largely unchanged[26]
- CDC MMWR 2022: Mesothelioma deaths among women increased from 1990 to 2020, contrasting with declining male mortality[26]
- Italian National Mesothelioma Registry: Non-occupational exposure was the predominant pathway in 45.3% of female mesothelioma cases versus 32.9% with occupational exposure[24]
- Only approximately 15–20 U.S. institutions maintain dedicated mesothelioma tumor boards, leaving the majority of 2,669 annual patients without specialized case review[20]
- Median age at mesothelioma diagnosis: 72–74 years, with incidence rates of 8.5 per 100,000 in patients aged 85 and older[4]
- Peritoneal mesothelioma with complete cytoreduction (CC-0) achieves median 104 months survival — an 8.7-year outcome accessible primarily at academic centers[23][12]
Get Help
Mesothelioma patients facing disparities in treatment access or who need guidance navigating specialist referrals can connect with experienced legal and medical advocates:
- Danziger & De Llano provides free case evaluations and can help coordinate referrals to specialized mesothelioma treatment centers — call (866) 222-9990
- Mesothelioma Lawyer Center offers comprehensive resources on treatment options, legal rights, and compensation pathways
- Mesothelioma.net provides information on specialized treatment centers and clinical trial access
- MesotheliomaAttorney.com offers guidance on asbestos trust fund claims that can fund treatment at specialized facilities
Related Pages
- Mesothelioma Prognosis — Prognostic factors, scoring systems, and survival data
- Mesothelioma Staging — TNM 9th edition staging and treatment by stage
- Mesothelioma Survival Statistics — Population-level survival data
- Mesothelioma Quick Facts — Core statistics and disease overview
- Veterans Mesothelioma Quick Reference — Military exposure and VA benefits
- Occupational Asbestos Exposure Quick Reference — High-risk occupations and OSHA limits
References
- ↑ 1.0 1.1 1.2 1.3 Mesothelioma Diagnosis, Danziger & De Llano.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma, Taioli E, Wolf AS, Flores RM. Disease Markers 2015. SEER analysis, n=13,734 (2000–2009).
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma, Rodriguez D, et al. JAMA Network Open 2023;6(3). NCDB analysis, n=1,389 (2004–2017).
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 U.S. Cancer Statistics: Malignant Mesothelioma, Centers for Disease Control and Prevention. Updated 2025. 63,620 cases from 2003–2022.
- ↑ 5.0 5.1 5.2 5.3 5.4 Mesothelioma Treatment Options, Mesothelioma Lawyer Center.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 Sex differences in mesothelioma, Van Gerwen M, et al. Thoracic Cancer 2020;11(11).
- ↑ 7.0 7.1 7.2 7.3 7.4 Vermiculite, Respiratory Disease, and Asbestos Exposure in Libby, Montana, Sullivan PA. Environmental Health Perspectives 2007;115(4).
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 Health and Environmental Studies in Ambler, Pennsylvania, U.S. Environmental Protection Agency. BoRit Asbestos Superfund Site, EPA Region 3.
- ↑ 9.0 9.1 9.2 Mesothelioma Compensation, Danziger & De Llano.
- ↑ 10.0 10.1 Demographic and racial characteristics, and survival trends in pleural mesothelioma: A population based study, Alalwan AA, et al. Journal of Clinical Oncology 2023;41(suppl 16):e20543. SEER analysis, n=13,166 (2000–2019).
- ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 A narrative review of the health disparities associated with malignant pleural mesothelioma, Keshavarz-Rahaghi F, Gao SJ. Translational Lung Cancer Research 2021;10(7).
- ↑ 12.0 12.1 12.2 12.3 12.4 Survival Outcomes for Malignant Peritoneal Mesothelioma: Academic vs. Community Hospitals, Yin K, et al. Annals of Surgical Oncology 2021. NCDB analysis.
- ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 Disparities in Clinical Research and Cancer Treatment, American Association for Cancer Research. AACR Cancer Disparities Progress Report 2024.
- ↑ 14.0 14.1 14.2 Malignant Mesothelioma, Danziger & De Llano.
- ↑ 15.0 15.1 15.2 15.3 Trends and survival of malignant mesothelioma across racial groups, Gupta S, et al. Journal of Clinical Oncology 2023;41(suppl 16):e20539.
- ↑ 16.0 16.1 16.2 Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients, Enewold L, et al. Journal of Immigrant and Minority Health 2020. NCDB analysis, n=2,550.
- ↑ Researchers Identify Disparities in Mesothelioma Treatment for Black and White Patients, Mesothelioma.net.
- ↑ 18.0 18.1 Types of Mesothelioma, Mesothelioma Lawyer Center.
- ↑ 19.0 19.1 Mesothelioma Treatment, Mesothelioma.net.
- ↑ 20.0 20.1 20.2 20.3 Malignant Mesothelioma Treatment (PDQ), National Cancer Institute.
- ↑ 21.0 21.1 Veterans and Mesothelioma, Danziger & De Llano.
- ↑ 22.0 22.1 Gender, race, and estrogen receptor expression in peritoneal mesothelioma, Patel SC, et al. World Journal of Surgical Oncology 2015;13:197.
- ↑ 23.0 23.1 Peritoneal Mesothelioma, Mesothelioma.net.
- ↑ 24.0 24.1 24.2 Analysis of latency time and its determinants in asbestos-related malignant mesothelioma cases of the Italian register, Marinaccio A, et al. ReNaM database, n=21,463 (1993–2012). Occupational and Environmental Medicine 2018.
- ↑ Mesothelioma Stages, Mesothelioma Lawyer Center.
- ↑ 26.0 26.1 26.2 Malignant Mesothelioma Mortality — United States, 1999–2020, Centers for Disease Control and Prevention. MMWR 2022;71(19).
- ↑ 27.0 27.1 27.2 27.3 Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials, Patel MI, et al. JCO Oncology Practice 2023. ASCO-ACCC quality improvement study.
- ↑ Mesothelioma, MesotheliomaAttorney.com.
- ↑ 29.0 29.1 Race and Superfund site remediation, Liévanos RS, et al. PNAS Nexus 2024;3(9). Analysis of 1,688 Superfund sites.
- ↑ 30.0 30.1 Mesothelioma Trust Funds, MesotheliomaAttorney.com.
- ↑ Living in the Town Asbestos Built, Science History Institute. History of Ambler, Pennsylvania asbestos contamination; Pennsylvania Department of Health study found mesothelioma rates 3.1 times higher in Ambler area.
- ↑ Mesothelioma Overview, Mesothelioma Lawyer Center.